ライフサイエンスコーパス: vaccination

1 current vaccination).

2 re T cells elicited after childhood smallpox vaccination.

3 in 4 cases, this occurred within 72 hours of vaccination.

4 navirus 2 (SARS-CoV-2) might be curtailed by vaccination.

5 ntussusception, particularly after rotavirus vaccination.

6 e marrow (BM) and blood up to 20 years after vaccination.

7 rations after the primary series and booster vaccination.

8 CD8 cross-reactivity in the context of HIV-1 vaccination.

9 y target the very host pathways activated by vaccination.

10 3 at week 54, more than 6 months after final vaccination.

11 immunocompetent adults aged >=50 years after vaccination.

12 elicitation of bNAbs and their precursors by vaccination.

13 accination(s), plus 2 weeks after the second vaccination.

14 to prevent a substantial shift toward early vaccination.

15 nalyses to evaluate control measures such as vaccination.

16 a protective IgG titer in the 10 years after vaccination.

17 No serious adverse events were related to vaccination.

18 antibodies to non-immunodominant epitopes by vaccination.

19 ent a general and potent strategy for cancer vaccination.

20 response and trace antibody lineages during vaccination.

21 protection from reinfection as conferred by vaccination.

22 st predicted neoepitopes not detected before vaccination.

23 h benefits and should be prioritised for HPV vaccination.

24 ditional doses administered 10Y post-initial vaccination.

25 approach to improve cellular immunity in flu vaccination.

26 s disease burden and the potential impact of vaccination.

27 have impaired Tfh cell differentiation upon vaccination.

28 creases or decreases in prevalence following vaccination.

29 ecific strongly neutralizing antibodies upon vaccination.

30 status influenced the effect of neonatal BCG vaccination.

31 ted to be a cost-effective alternative to no vaccination.

32 ivery applications, including multicomponent vaccination.

33 e measured from plasma samples pre- and post-vaccination.

34 lowed response decay compared to the 6-month vaccination.

35 ponders compared to high responders prior to vaccination.

36 to long-lasting immunity after infection or vaccination.

37 ecipients years after different schedules of vaccination.

38 p study was carried out for 1 year following vaccination.

39 lts 15-35 years after the start of varicella vaccination.

40 vaccinated mothers after primary and booster vaccination.

41 izing Ab responses should facilitate booster vaccinations.

42 despite decades of bats culls and livestock vaccinations.

43 onal age, 30 weeks), complete samples before vaccination, 1 month after the primary series, and 1 mon

44 second (20.0% vs 14.6%, p = 0.33) and third vaccination (14.9% vs 23.4%, p = 0.22).

45 Median age at vaccination (18.7 years) was older than age at first sex

46 th vaccination than 2 weeks after the fourth vaccination: 87.7% versus 75.4% (difference = 12.3%, 95%

47 In the second year after vaccination, a decline in efficacy was observed [56.2% (

48 ease in activated CD8+ T cells after CYD-TDV vaccination, a phenomenon that was greatest for the JE v

49 the frequency of indications for hepatitis A vaccination according to Advisory Committee on Immunizat

50 onic viral infection on T-cell responses and vaccination against highly pathogenic viruses are not we

51 In this study, we used DNA vaccination against the MACV glycoprotein precursor comp

52 Universal childhood vaccination against varicella began in the United States

53 Our health economic appraisal sweeps vaccination age space to determine threshold vaccine dos

54 become colonized and transmit; consequently, vaccination alone can only interrupt transmission in 28%

55 Compared to the status quo, by 2030, vaccination alone would have minimal impact on cervical

56 By 2070, scaling up vaccination alone would reduce mortality by 61.7% (61.4-

57 By 2120, vaccination alone would reduce mortality by 89.5% (86.6-

58 Importantly, intratumoral vaccination also provides protection against subsequent

59 Therapeutic vaccination also reduced fentanyl intravenous self-admin

60 CHMI, but not vaccination, also induced the activation of TCR Vdelta1

61 enzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously vaccinated children treated

62 Vaccination and accurate influenza diagnosis may curb un

63 showed no association between prenatal Tdap vaccination and ADHD in offspring (hazard ratio = 1.00,

64 Influenza vaccination and antiviral administration could be increa

65 HPV vaccination and cervical cancer screening for women livi

66 erapy and could potentially be developed for vaccination and chemotherapy drug transportation.

67 ull hypothesis of no association between BCG vaccination and COVID-19 mortality, and suggest that BCG

68 broad-spectrum antiinfluenza therapeutic, as vaccination and existing treatments are only moderately

69 were similar for second and third-trimester vaccination and for analyses considering major malformat

70 an parenteral delivery; in both conventional vaccination and heterologous boosting of parenteral BCG

71 t older individuals mount to influenza virus vaccination and infection is critical in order to design

72 vide help to B cells was evident during both vaccination and infection.

73 bal Polio Eradication Initiative, as well as vaccination and population data from publicly available

74 here, and to establish causality between BCG vaccination and protection from severe COVID-19.

75 unctions early after Ad26.ZEBOV, MVA-BN-Filo vaccination and provides a mechanism for the activation

76 improving on the partial efficacy of gB/MF59 vaccination and should be further evaluated in preclinic

77 ing for other TB risk factors (age, sex, BCG-vaccination and stays >=3 months in Africa/Asia).

78 nvestigate the association between influenza vaccination and the risk of CVDs.

79 Responses to vaccination and to diseases vary widely across individua

80 nificantly changes the ability to respond to vaccinations and infections.

81 h disease-induced mortality on harvest rate, vaccination, and disinfection behaviors.

82 f strategies concerning antiviral treatment, vaccination, and epidemiological control stands crucial.

83 doses was assessed through 10Y post-initial vaccination, and modeled through 20Y using a Piecewise,

84 hology and accordingly the immunotherapeutic vaccination approach targeting IL-31 alleviated clinical

85 Oncolytic viruses offer an in situ vaccination approach to activate tumor-specific T cell r

86 ng antibody responses, with implications for vaccination approaches and schedules.

87 Clinical trials using whole-sporozoite-based vaccination approaches such as the Sanaria PfSPZ Vaccine

88 s of the local burden and the past impact of vaccination are therefore increasingly needed, but diffi

89 infection, malaria and influenza, effective vaccinations are still lacking.

90 rmine carcinogenic effects and impact of HPV vaccinations are warranted, especially in sub-Saharan Af

91 re has not been a dominant IPD serotype post-vaccination as there was pre-vaccination (serotype 14) o

92 Blood was collected before vaccination, as well as at 1 day, 4 days, 2 weeks, and 3

93 timated for three core scenarios: girls-only vaccination at age 9 years with catch-up for girls aged

94 The exposure of interest was PPV23 vaccination at any time point prior to the index admissi

95 We found that the observed vaccination behavior in the Israeli OPV campaign is attr

96 and monocyte activation that occur after BCG vaccination but do not support the hypothesis that BCG v

97 during secondary immune responses and after vaccination by synergy with effector T cells and virus-s

98 Vaccination campaign coverage was consistent with seropr

99 potential correlates of risk during an Ebola vaccination campaign in an outbreak.

100 d introductions; and a one-time, large-scale vaccination campaign.

101 aged 9-14 years at the time of a mass dengue vaccination campaign.

102 n September and November 2017, respectively, vaccination campaigns targeting children <15 years old w

103 Because influenza vaccination can be poorly effective some years, and the

104 Biomaterial-based AML vaccination can induce potent immune responses, deplete

105 tection may seem better than none, imperfect vaccination can present epidemiological, ecological, and

106 cess risk of COVID-19 deaths associated with vaccination clinic visits, especially for the vaccinated

107 BCG vaccination clinical trials are required to corroborate

108 ters in the main online network, whereas pro-vaccination clusters are more peripheral.

109 Although smaller in overall size, anti-vaccination clusters manage to become highly entangled w

110 In phase 1, vaccination comprised two intramuscular injections, 21 d

111 Reducing apoptosis signalling via in situ vaccination could be a versatile strategy for the genera

112 results of the RV144 trial demonstrated that vaccination could prevent HIV transmission in humans and

113 rth year, maternal age, and age-specific HPV vaccination coverage as independent variables.

114 nfection of transport vehicles twice a week, vaccination coverage could be lowered to 60% in the best

115 This is important, as pneumococcal vaccination coverage in PLWH is low in Europe and the Un

116 s encephalitis was infrequent following high vaccination coverage since 2007.

117 n of schools below a high-risk threshold for vaccination coverage, and five-year trends in CVEs.

118 derately high background levels of influenza vaccination coverage, SLIV programs are associated with

119 ngthen immunization programs to achieve high vaccination coverage; some must undertake strategies to

120 Generating durable humoral immunity through vaccination depends upon effective interactions of folli

121 BCG vaccination did not alter levels of antibodies against h

122 Despite these effects, BCG vaccination did not increase the rate of SIV oral transm

123 n in the draining lymph node 12 h after s.c. vaccination directly correlates with downstream CD8(+) T

124 er immunotherapies, particularly therapeutic vaccination, do not typically generate robust anti-tumou

125 ity following natural infection and Zostavax vaccination dominantly targets nonstructural (NS) protei

126 The results may not be generalizable to vaccinations done in other types of health care settings

127 d before 5 years of age by routine childhood vaccination during a 6-month COVID-19 risk period withou

128 s article describes a reduction in childhood vaccinations during the COVID-19 pandemic, which may lea

129 nge size increases RABV spread and decreases vaccination effectiveness in host populations following

130 Enhanced vaccination efforts are critically needed, particularly

131 As wide-scale vaccination efforts grow more urgent amid the current CO

132 to estimate global risk of YF outbreaks and vaccination efforts needed to achieve elimination of YF

133 TSCompared with evening vaccination, morning vaccination elicited both a stronger trained immunity an

134 Influenza vaccination gave meaningful protection against laborator

135 s who received checkpoint blockade before DC vaccination had higher baseline MA-specific CD8 T cell r

136 eased risk of intussusception with rotavirus vaccination has been found.

137 BCG vaccination has recently been proposed as a strategy to

138 high-prevalence populations, adult catch-up vaccination has sometimes been deployed, but an alternat

139 Vaccination has transformed public health, most notably

140 nger, and 85.8% of the patients with a known vaccination history were unvaccinated.

141 l blood mononuclear cells collected prior to vaccination identified 53 differentially phosphorylated

142 understood for 2-dose inactivated influenza vaccination (IIV) schedules in autologous haematopoietic

143 Retrospective studies suggest that HPV vaccination improves response to treatment of cervical H

144 24-58%) or without (33%;95%CI=-16-64%) prior vaccination in 2015-16.

145 These data demonstrate that Zika vaccination in a DENV-experienced individual can boost p

146 In contrast, the impact of catch-up vaccination in adults had a negligible and transient eff

147 d CD8(+) T cell responses were observed post-vaccination in all of the patients.

148 within 1-7, 8-21, and 1-21 days of rotavirus vaccination in children aged 28-275 days at onset of sym

149 -effectiveness of human papillomavirus (HPV) vaccination in girls.

150 Seasonal influenza vaccination in humans primarily stimulates pre-existing

151 inal centre B cell responses after influenza vaccination in humans.

152 results support the importance of influenza vaccination in older adults, who account for most influe

153 rted as an adverse event after intramuscular vaccination in the deltoid muscle.

154 Restricting the analysis to vaccination in the first trimester of pregnancy did not

155 highly effective in vivo priming by peptide vaccination in the presence of proper adjuvants or in vi

156 f influenza-associated outcomes prevented by vaccination in the United States.

157 to their therapeutic modulation or roles in vaccination in these diseases.

158 irculating antibody specificities induced by vaccination in these two canarypox prime-protein boost t

159 Similarly, more frequent/recent vaccinations in children and younger populations may res

160 indings provide a mechanistic basis for VACV vaccination-induced heterotypic immunity which can prote

161 Experimentally, airway vaccination induces greater efficacy than parenteral del

162 n but do not support the hypothesis that BCG vaccination is a risk factor for postnatal HIV transmiss

163 It is concluded that vaccination is a social contract in which cooperation is

164 gh recent studies suggest that maternal Tdap vaccination is effective at preventing infant disease, n

165 CD8+ T cell response to vaccination is impaired as a result of cDC1 dysregulatio

166 rather than focusing on those hesitant about vaccination is likely to have the population health bene

167 imicrobial resistance, and therefore typhoid vaccination is recommended as a preventive measure.

168 The textbook view of vaccination is that it functions to induce immune memory

169 Vaccination is the most effective way to prevent influen

170 Tdap vaccination led to short-term potentiation and long-term

171 rd doses of ChAdOx1 nCoV-19, after the prime vaccination local reactions were reported in 43 (88%) of

172 Six months after BCG vaccination, macaques were challenged with virulent Mtb.

173 The higher responses after rHA vaccination may be due to its higher HA content.

174 cent studies have assessed whether rotavirus vaccination modifies T1D development, finding null or pr

175 12 pm with BCG.RESULTSCompared with evening vaccination, morning vaccination elicited both a stronge

176 We used a 24-week guinea pig vaccination-Mycobacterium tuberculosis (M.tb.) challenge

177 The health benefits of vaccination of 12-year-old girls were estimated to be si

178 ar but slightly decreased in comparison with vaccination of 9-year-old girls.

179 ired by experiments by Dunbar on the passive vaccination of allergic animals more than 100 years ago.

180 Human papillomavirus (HPV) vaccination of girls with very high (>90%) coverage has

181 n programmes, ongoing PMTCT efforts, and the vaccination of high-risk groups, diagnosing and treating

182 to control Lyme disease that bypassed direct vaccination of the human host.

183 lth authorities in some countries prioritize vaccination of this population.

184 We show, however, that low-coverage vaccination of tigers themselves is feasible and would p

185 Vaccination offered no protection against A(H1N1)pdm09 v

186 igated the effects of M.tb infection and BCG vaccination on B cell responses to heterologous pathogen

187 oes support the protective role of influenza vaccination on CVDs events.

188 n, it is important to evaluate the effect of vaccination on disease severity.

189 effectiveness of preventive therapy and BCG vaccination on the risk of developing tuberculosis.

190 :8) at baseline to seropositive (>1:8) after vaccination or boosting titers by >4-fold for those with

191 prevented by reducing the exposure to HBV by vaccination or by treatment of CHB infection.

192 ould have the greatest benefit from starting vaccination or from scaling up existing programs and wil

193 tients who tested nonimmune were offered MMR vaccination or intravenous immunoglobulin depending on t

194 se cannot be reliably predicted after either vaccination or treatment with antibodies-regardless of w

195 ctiveness of three components of oral rabies vaccination (ORV) programmes targeting raccoons-timing a

196 rse events were more common after the second vaccination, particularly with the highest dose, and thr

197 ch-up for girls aged 10-14 years; girls-only vaccination plus once-lifetime screening and cancer trea

198 nd cancer treatment scale-up; and girls-only vaccination plus twice-lifetime screening and cancer tre

199 of COVID-19 in countries with universal BCG vaccination policies.

200 rates, there was no association between BCG vaccination policy and COVD-19 spread rate or percent mo

201 Supported by this analysis, the vaccination program in Finland now recommends LAIV4 and

202 In October 2012 a maternal pertussis vaccination program was introduced in England for women

203 The model predicts that the current U.S. HPV vaccination program will reduce the number of diagnoses

204 009 introduction of HPV vaccine to Denmark's vaccination program.

205 In general, the addition of low-risk vaccination programmes whose coverage encompassed childr

206 In countries with stronger historical vaccination programs and higher country income, case pat

207 ecause of the high coverage of international vaccination programs, most people worldwide have been va

208 maturation continued for 6 to 9 mo following vaccination, providing evidence for the persistence of g

209 ausibly similar along most dimensions except vaccination rate.

210 in 2019, despite achieving national measles vaccination rates above the World Health Organization re

211 n predicting disease risk posed by measuring vaccination rates at coarse spatial scales.

212 Racial and ethnic disparities in vaccination rates for seasonal influenza exist.

213 uding universal childhood hepatitis A (HepA) vaccination recommendations in 2006, hepatitis A virus (

214 nd after the implementation of universal HBV vaccination recommendations were determined.

215 s of vaccine failures and to optimize future vaccination recommendations.

216 nonstructural (NS) proteins, while Shingrix vaccination redirects dominant reactivity to target gE.

217 Prophylactic vaccination reduced fentanyl- and sufentanil-induced ant

218 BCG vaccination reduced the risk of a positive baseline IGRA

219 One healthcare visit for a potential vaccination-related symptom (urticaria) was reported.

220 y, the method, source and origin of smallpox vaccinations remained unstandardised and opaque.

221 Efficacious HIV-1 vaccination requires elicitation of long-lived antibody

222 le cells from healthy high and low influenza vaccination responders revealed that our signatures refl

223 arge cohort of 302 volunteers, early morning vaccination resulted in a superior cytokine production c

224 Vaccination results in the development of Th1, Th17, and

225 We assessed vaccination's potential impact and the feasibility of ac

226 days, 2 weeks, and 3 months after the first vaccination(s), plus 2 weeks after the second vaccinatio

227 19, 2019, to Jan 13, 2029, we compared a no vaccination scenario with five OCV campaign scenarios th

228 Although the sequential vaccination schedule of PCV13 followed by PPSV23 is safe

229 as TBE despite adherence to the recommended vaccination schedule with at least 2 doses.

230 Screening was conducted over two influenza vaccination seasons, 2017-2018 and 2018-2019, in four GP

231 D serotype post-vaccination as there was pre-vaccination (serotype 14) or post-PCV7 (serotype 19A), s

232 RS-CoV-2) infection through visiting routine vaccination service delivery points.

233 ferences in cross-reactivity after influenza vaccination should be expected in individuals with diffe

234 Therefore, preferably, vaccinations should be administered before the initiatio

235 tices, drug treatment, and hepatitis A and B vaccinations should be key components of viral hepatitis

236 Residents' influenza vaccination status (vaccinated, refused, and not offered

237 Both sex and maternal BCG vaccination status influenced the effect of neonatal BCG

238 results varied by season, influenza status, vaccination status, and age.

239 died the effect of age, baseline viral load, vaccination status, antiviral therapy, and emergence of

240 Clinical data recorded were medical history, vaccination status, type of IPD, clinical features, and

241 measured confounding, and caregiver-reported vaccination status, which is subject to poor recall and

242 ovide critical information for the design of vaccination strategies intended to provoke cell-mediated

243 ramework for improved design of age-specific vaccination strategies that require further evaluation i

244 90% during 2018-2030, by comparing realistic vaccination strategies under a range of scenarios of vac

245 ave major implications for the design of new vaccination strategies with adoptive T cell therapy.

246 mportant proxy for determining potential RSV vaccination strategies.

247 for the development of both therapeutic and vaccination strategies.

248 vantages of a diversity of anti-pneumococcal vaccination strategies.

249 gladesh, to assess polio immunity and inform vaccination strategies.

250 ct (HE) depends both on the HPV type and the vaccination strategy.

251 from which to optimize future messenger RNA vaccination studies against NiV and other highly pathoge

252 Vaccination studies in the A/J mouse model showed that t

253 ence highlights neuraminidase as a potential vaccination target.

254 antigens were higher 2 weeks after the fifth vaccination than 2 weeks after the fourth vaccination: 8

255 of immune responses was seen after the fifth vaccination than after the fourth, with higher antibody

256 4 adverse events (AEs) within 2 weeks after vaccination that were probably or definitely attributabl

257 Additionally, the influence of vaccination time on induction of trained immunity was st

258 This study did not support HPV vaccination to prevent recurrent HSIL after LEEP in wome

259 ent danger to global health as new tools for vaccination, treatment, and interruption of transmission

260 registered to inform on the benefits of BCG vaccinations upon exposure to CoV-2.

261 ntibiotic prescriptions averted by influenza vaccination using estimates of VE, coverage, and prevale

262 d women 10 to 30 years old, quadrivalent HPV vaccination was associated with a substantially reduced

263 Vaccination was associated with transient mild to modera

264 ing the studied influenza seasons, influenza vaccination was at least modestly effective in reducing

265 If vaccination was combined with cleaning and disinfection

266 adjusted analyses, prenatal exposure to H1N1 vaccination was not associated with a later diagnosis of

267 Blood collected before and after vaccinations was tested for poliovirus-neutralizing anti

268 ed in a clinical trial of maternal influenza vaccination, we estimate incidence of RSV-associated feb

269 The effects of age at BCG and time since vaccination were also explored.

270 accine-specific antibody responses following vaccination were further analyzed.

271 The rates of local reactions related to vaccination were similar between vaccine arms (3AV vs 1A

272 Adjusted odds ratios for vaccination with 1, 2, and 3 doses were 0.53 (95% confid

273 n of rotavirus has been altered by rotavirus vaccination with a biennial disease pattern, sustained l

274 Vaccination with a combination of the single-antigen vec

275 lly infected with CL13 could be protected by vaccination with a highly attenuated variant of ECTV.

276 These results highlight that even partial vaccination with a leaky vaccine can have unforeseen pos

277 disease virus (MDV) in chickens to show that vaccination with a leaky vaccine substantially reduces v

278 Natural infections and vaccination with a pathogen typically stimulate the prod

279 Interventions, including mass vaccination with a Vi-conjugate vaccine coadministered w

280 We found that vaccination with Ad4-prM-E leads to the development of a

281 ting significant anti-ZIKV antibodies, while vaccination with Ad5-prM-E leads to the development of b

282 pared the antibody responses in humans after vaccination with an AS03-adjuvanted versus nonadjuvanted

283 Vaccination with both vaccines prevented fever and prote

284 We also found that vaccination with CspZ, but not CspZ-YA, triggered the pr

285 Postchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immu

286 n to improve protective efficacy compared to vaccination with each single-antigen vector alone.

287 Vaccination with formalin-inactivated "rewired" viruses

288 ice had a dose-sparing effect for subsequent vaccination with fusion proteins containing the Ag 85B e

289 A single-dose vaccination with JENVAC induces protective titers that p

290 Conversely, vaccination with MF59 recruited NK cells poorly and drov

291 Vaccination with NPs loaded with H1N1 Flu antigen, R848,

292 We compared antibody responses to vaccination with recombinant E1E2 complex in healthy vol

293 Chemoprophylaxis vaccination with sporozoites (CVac) with chloroquine ind

294 heterologous immune responses is induced by vaccination with Tdap and BCG, and more studies are warr

295 g, sera from human subjects before and after vaccination with the 13-valent-conjugated Streptococcus

296 es the anti-NA antibody response compared to vaccination with unmodified viruses.

297 Vaccination with vaccinia virus (VACV) elicits heterotyp

298 de C Env binding antibodies after the second vaccination, with higher total IgG titres after the tetr

299 All models assumed CMV vaccination would prevent primary infection and 2 models

300 pulations following pathogen invasion into a vaccination zone.